公开(公告)号：US20170298132A1

公开(公告)日：2017-10-19

申请号：US15623572

申请日：2017-06-15

Applicant: INNATE PHARMA

Inventor： CECILE BONNAFOUS ,  HELENE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61K39/00

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/3023 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N33/57426 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20190127463A1

公开(公告)日：2019-05-02

申请号：US16240906

申请日：2019-01-07

Applicant: INNATE PHARMA

Inventor： CECILE BONNAFOUS ,  HELENE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20160136272A1

公开(公告)日：2016-05-19

申请号：US14890921

申请日：2014-05-13

Applicant: INNATE PHARMA

Inventor： RENAUD BUFFET ,  CARINE PATUREL

IPC: A61K39/395 ,  C07K16/28 ,  A61K31/573

CPC classification number: A61K39/3955 ,  A61K31/573 ,  A61K2039/505 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  A61K31/00

Abstract: The present invention relates to use of therapeutic agents that specifically bind and inhibit TLR3 signalling in order to sensitize patients to treatment with corticosteroids, notably for the treatment and prevention of inflammatory and autoimmune disorders.

Abstract translation: 本发明涉及特异性结合和抑制TLR3信号传导的治疗剂的用途，以使患者敏感地用皮质类固醇治疗，特别是用于治疗和预防炎性和自身免疫性疾病。

公开(公告)号：US20250092130A1

公开(公告)日：2025-03-20

申请号：US18823932

申请日：2024-09-04

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  A61K39/00 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20190315857A1

公开(公告)日：2019-10-17

申请号：US16451051

申请日：2019-06-25

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET ,  MATHIEU BLERY

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US20160002345A1

公开(公告)日：2016-01-07

申请号：US14769158

申请日：2014-02-20

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET

IPC: C07K16/30 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K16/3023 ,  C07K16/3061 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/732 ,  G01N33/57426 ,  G01N2333/705 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The disclosure also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Abstract translation: 本公开涉及使用特异性结合KIR3DL2的化合物治疗，预防和诊断外周T细胞淋巴瘤的方法。 本公开还涉及在诊断和鉴定测定中特异性结合KIR3DL2的抗体在检测和治疗外周T细胞淋巴瘤中的用途。

公开(公告)号：US20240425586A1

公开(公告)日：2024-12-26

申请号：US18731443

申请日：2024-06-03

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET ,  MATHIEU BLERY

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnosis of peripheral T-cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express NKp46 at their surface, and pharmaceutical compositions comprising the same. The disclosure also relates to the use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T-cell lymphoma.

公开(公告)号：US20210363248A1

公开(公告)日：2021-11-25

申请号：US17388052

申请日：2021-07-29

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÈNE SICARD ,  RENAUD BUFFET

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

Abstract: The present invention relates to methods for the treatment, prevention and diagnosis of peripheral T cell lymphoma using compounds that specifically bind KIR3DL2. The invention also relates to use of antibodies that specifically bind KIR3DL2 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

公开(公告)号：US20150376274A1

公开(公告)日：2015-12-31

申请号：US14767600

申请日：2014-02-13

Applicant: INNATE PHARMA

Inventor： CÉCILE BONNAFOUS ,  HÉLÉNE SICARD ,  RENAUD BUFFET ,  MATHIEU BLERY

IPC: C07K16/28 ,  G01N33/574

CPC classification number: C07K16/28 ,  C07K16/2803 ,  C07K16/3061 ,  C07K2317/73 ,  C07K2317/732 ,  G01N33/57407 ,  G01N2333/70503

Abstract: The present disclosure relates to methods for the treatment, prevention and diagnostic of peripheral T cell lymphoma using compounds that specifically bind NKp46. Included in particular are compounds that bind NKp46 and deplete tumor cells that express at their surface NKp46, and pharmaceutical compositions comprising the same. The disclosure also relates to use of antibodies that specifically bind NKp46 in diagnostic and theranostic assays in the detection and treatment of peripheral T cell lymphoma.

Abstract translation: 本公开涉及使用特异性结合NKp46的化合物治疗，预防和诊断外周T细胞淋巴瘤的方法。 特别包括结合NKp46并消耗在其表面NKp46表达的肿瘤细胞的化合物和包含其的药物组合物。 本公开还涉及在诊断和鉴定测定中特异性结合NKp46的抗体在检测和治疗外周T细胞淋巴瘤中的用途。